VivoSeq
Ophthalmology

Retinal Degeneration

3

Pipeline Programs↗

6

Active Trials↗

2

Companies Involved↗

Retinal Degeneration is an early-stage landscape with 3 programs across 2 companies. The most active players are Horizon Therapeutics Ireland DAC, Teva.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Horizon Therapeutics Ireland DAC

1 program

Phase 1Teva logo

Teva

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Interferon Gamma-1b

Horizon Therapeutics Ireland DAC

Phase 22

Disulfiram

Teva

Aav8.hlca5

Opus Genetics, Inc

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSGene therapy133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting5 · 83%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Recruiting·UUniversity of Rochester·Phase 1·NCT06319872·15 enrolled
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
Recruiting·OOpus Genetics, Inc·Phase 1/2·NCT05616793·22 enrolled
Disulfiram for Treatment of Retinal Degeneration
Recruiting·UUniversity of Washington·Phase 1/2·NCT05626920·30 enrolled
Rod and Cone Mediated Function in Retinal Disease
Recruiting·National Eye Institute (NEI)·N/A·NCT02617966·500 enrolled
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Recruiting·JJaeb Center for Health Research·N/A·NCT05589714·1,500 enrolled
Natural History of ABCA4-Related Retinopathies
Active, not recruiting·National Eye Institute (NEI)·N/A·NCT01736293·68 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)